-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Cqxe4/uJaux3N/YJBHVWuB7d74EZVl8HptsowKWDPDrmeYTIsQVyM+XH9M+F8aPH wTWrEHiGhsTR0wGq5s1Wtw== 0000950103-03-000719.txt : 20030314 0000950103-03-000719.hdr.sgml : 20030314 20030314104230 ACCESSION NUMBER: 0000950103-03-000719 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20030314 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ARADIGM CORP CENTRAL INDEX KEY: 0001013238 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943133088 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-46237 FILM NUMBER: 03603301 BUSINESS ADDRESS: STREET 1: 3929 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: 5102659000 MAIL ADDRESS: STREET 1: 3929 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: NOVO NORDISK A S CENTRAL INDEX KEY: 0000353278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: NOVO ALLE DK 2880 CITY: BAGSVAERD DENMARK STATE: G7 ZIP: 00000 BUSINESS PHONE: 4544448888 MAIL ADDRESS: STREET 1: NOVO ALLE DK 2880 CITY: BAGSVAERD DENMARK STATE: G7 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: NOVO INDUSTRI A S /DENMARK/ DATE OF NAME CHANGE: 19890811 FORMER COMPANY: FORMER CONFORMED NAME: NOVO NORDISK A/S DATE OF NAME CHANGE: 19900807 SC 13D/A 1 ma1103-13da3.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ----------------------- SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)1 ARADIGM CORPORATION ________________________________________________________________________________ (Name of Issuer) Common Stock, no par value ________________________________________________________________________________ (Title of Class of Securities) 038508 ________________________________________________________________________________ (CUSIP Number) Ole Ramsby Novo Nordisk A/S Novo Alle DK-2880 Bagsvaerd Denmark Tel No.: +45 4444 8888 ________________________________________________________________________________ (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) March 10, 2003 ________________________________________________________________________________ (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box [ ]. Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. - ----------------------- 1 The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the th purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13D CUSIP No. 038508 Page 2 of 10 Pages - ---------------------------------------- ------------------ 1 NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Novo Nordisk A/S - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)|_| (b)|_| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* OO - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) |_| - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION The Kingdom of Denmark - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 1,020,612 ----------------------------------------------- WITH NUMBER OF SHARES 8 SHARED VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,847,757 ----------------------------------------------- 9 SOLE DISPOSITIVE POWER 1,020,612 ----------------------------------------------- 10 SHARED DISPOSITIVE POWER 6,847,757 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,868,369 - See Item 5 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES |_| CERTAIN SHARES* - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 15.7% - See Item 5 - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! Page 2 of 10 Novo Nordisk A/S, a publicly quoted Danish company ("Buyer") hereby amends and supplements its Report on Schedule 13D, originally filed on November 14, 2001 (as amended and supplemented, the "Schedule 13D") with respect to the shares of Common Stock, no par value (the "Shares"), of Aradigm Corporation, a California corporation (the "Issuer"). Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Schedule 13D. Item 1. Security and Issuer. Item 2. Identity and Background. Item 3. Source and Amount of Funds or Other Consideration. Item 4. Purpose of Transaction. The following additional paragraphs are added after the last paragraph of Item 4 of the Schedule 13D: The transactions pursuant to the Securities Purchase Agreement closed on March 10, 2003. The Voting Agreement also terminated on March 10, 2003 in accordance with its terms. As a result, Buyer is no longer deemed to have the shared power to vote or direct the vote of the securities of the Issuer held by the Other Stockholders. Item 5. Interest in Securities of the Issuer. (a) For the purposes of Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), Buyer may be deemed to beneficially own 7,868,369 Shares, or approximately 15.7% of the outstanding Shares. (b) By virtue of the relationship described in Item 2 of this Schedule 13D, Buyer may be deemed to have the sole power to vote or direct the vote and sole power to dispose or direct the disposition of and vote of the 1,020,612 Shares held by it directly and the shared power to direct the disposition of and vote of the 6,847,757 Shares held by NN Pharmaceuticals. (c) None of Buyer, any of the persons named in Item 2 or any of the persons set forth on Schedule A, has effected any transaction in the Common Stock during the past 60 days. (d) Inapplicable. (e) Inapplicable. Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. See response to Item 4. Item 7. Material to be Filed as Exhibits. Exhibit 1: Stock Purchase Agreement dated as of October 22, 2001 between the Issuer and Buyer.# Exhibit 2: Voting Agreement dated as of February 10, 2003 between Buyer and certain other parties set forth on Exhibit A to such Voting Agreement.@ Page 3 of 10 # Previously filed as an exhibit to the original Schedule 13D filed November 14, 2001. @ Previously filed as an exhibit to Amendment No. 2 to the Schedule 13D filed February 28, 2003. Page 4 of 10 SIGNATURES After reasonable inquiry and to the best knowledge and belief of the undersigned, the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: March 14, 2003 NOVO NORDISK A/S By: /s/ Lars Rebien Sorensen ---------------------------------------- Name: Lars Rebien Sorensen Title: Chief Executive Officer By: /s/ Kare Schultz ---------------------------------------- Name: Kare Schultz Title: Executive Vice President Page 5 of 10 SCHEDULE A DIRECTORS AND EXECUTIVE OFFICERS OF BUYER The name, address, title, present principal occupation or employment of each of the directors and executive officers of Buyer are set forth below. If no address is given, the director's or officer's address is Novo Alle, DK-2880 Bagsvaerd, Denmark. The directors are designated with asterisks (*). Name and Citizenship Principal Occupation and Address - -------------------------------------------------------------------------------- *Mads 0vlisen Chairman of the Board Danish Novo Nordisk A/S Novo Alle, 6B2.22 2880 Bagsvaerd Denmark - -------------------------------------------------------------------------------- *Kurt Anker Nielsen Co-President & CEO Danish Novo A/S Krogsh0jvej 41, 9P2.05 2880 Bagsvaerd Denmark - -------------------------------------------------------------------------------- *Jan Ulf Sigvard Johansson CEO/Businessman Swedish Strandvagen 43, 4 tr. 114 56 Stockholm Sweden - -------------------------------------------------------------------------------- *J0rgen Wedel 29 Winsor Way Danish Weston, Massachusetts 02493 USA - -------------------------------------------------------------------------------- *Kurt Briner Director Swiss c/o Ebsa sa 47, rue du 31 Decembre CH-1211 Geneva 6 Switzerland - -------------------------------------------------------------------------------- *Niels Jacobsen President & CEO Danish William Demant Holding A/S Strandvejen 58 2900 Hellerup Denmark - -------------------------------------------------------------------------------- *Anne Marie Handrup Kverneland Laboratory Assistant Danish Novo Nordisk A/S Laurentsvej 22, 7X 2880 Bagsvaerd Denmark - -------------------------------------------------------------------------------- Page 6 of 10 Name and Citizenship Principal Occupation and Address - -------------------------------------------------------------------------------- *Johnny Henriksen Environmental Specialist Danish Novo Nordisk A/S Hummeltoftevej 49 Building SOC 1.18 2830 Virum Denmark - -------------------------------------------------------------------------------- *Stig Str0baek Electrician Danish Novo Nordisk, A/S Laurentsvej 22, 7X 2880 Bagsvaerd Denmark - -------------------------------------------------------------------------------- Lars Rebien S0rensen CEO Danish Novo Nordisk A/S - -------------------------------------------------------------------------------- Jesper Brandgaard CFO Danish Novo Nordisk A/S - -------------------------------------------------------------------------------- Kare Schultz Chief Operating Officer Danish Novo Nordisk A/S - -------------------------------------------------------------------------------- Mads Krogsgaard Thompsen Chief Science Officer Danish Novo Nordisk A/S - -------------------------------------------------------------------------------- Lars Almblom J0rgensen Chief of Staffs Danish Novo Nordisk A/S - -------------------------------------------------------------------------------- Lise Kingo Executive Vice President Danish Novo Nordisk A/S - -------------------------------------------------------------------------------- DIRECTORS AND EXECUTIVE OFFICERS OF NN NORTH AMERICA The name, address, title, present principal occupation or employment of each of the directors and executive officers of NN North America, are set forth below. If no address is given, the director's or officer's address is 405 Lexington Avenue, New York City, New York 10017. The directors are designated with asterisks (*). Name and Citizenship Principal Occupation and Address - -------------------------------------------------------------------------------- *James Shehan President and Secretary USA Novo Nordisk of North America, Inc. - -------------------------------------------------------------------------------- *Susan Jackson Vice President Communications USA Novo Nordisk Pharmaceuticals, Inc. 100 College Road West Princeton, NJ 08540-7810 - -------------------------------------------------------------------------------- *Phil Fornecker CFO and Treasurer USA Novo Nordisk of North America, Inc. - -------------------------------------------------------------------------------- Page 7 of 10 Name and Citizenship Principal Occupation and Address - -------------------------------------------------------------------------------- *Ole F. Ramsby Senior Vice President Legal Affairs Danish and General Counsel Novo Nordisk A/S Novo Alle 2880 Bagsvaerd Denmark - -------------------------------------------------------------------------------- Mark Stolp Assistant Treasurer USA Novo Nordisk of North America, Inc. - -------------------------------------------------------------------------------- Jerry Shilling Assistant Treasurer USA Novo Nordisk of North America, Inc. - -------------------------------------------------------------------------------- Kevin Rowland Assistant Treasurer USA Novo Nordisk of North America, Inc. - -------------------------------------------------------------------------------- Joan M. Schmidt Assistant Secretary USA Novo Nordisk of North America, Inc. - -------------------------------------------------------------------------------- DIRECTORS AND EXECUTIVE OFFICERS OF NN PHARMACEUTICALS The name, address, title, present principal occupation or employment of each of the directors and executive officers of NN Pharmaceuticals, are set forth below. If no address is given, the director's or officer's address is 100 College Road, Princeton, New Jersey 08540. The directors are designated with asterisks (*). Name and Citizenship Principal Occupation and Address - -------------------------------------------------------------------------------- *Martin Soeters President The Netherlands Novo Nordisk Pharmaceuticals, Inc. - -------------------------------------------------------------------------------- *Kare Schultz Chief Operating Officer Danish Novo Nordisk A/S - -------------------------------------------------------------------------------- *Barry Reit Vice President Regulatory Affairs USA Novo Nordisk Pharmaceuticals, Inc. - -------------------------------------------------------------------------------- *Phil Fornecker Vice President Finance USA Novo Nordisk Pharmaceuticals, Inc. - -------------------------------------------------------------------------------- *Jim C. Shehan President USA Novo Nordisk of North America, Inc. 405 Lexington Avenue New York City, NY 10017 - -------------------------------------------------------------------------------- DIRECTORS AND EXECUTIVE OFFICERS OF NOVO A/S The name, address, title, present principal occupation or employment of each of the directors and executive officers of Novo A/S, are set forth below. If no address is given, the director's or officer's Page 8 of 10 address is Krogsh0jvej 41, DK-2880 Bagsvaerd, Denmark. The directors are designated with asterisks (*). Name and Citizenship Principal Occupation and Address - -------------------------------------------------------------------------------- *Palle Marcus Chairman of the Board of Directors Danish Novo A/S - -------------------------------------------------------------------------------- *J0rgen Boe Lawyer Danish Margrethevej 6 2960 Rungsted Kyst Denmark - -------------------------------------------------------------------------------- *Jan Ulf Sigvard Johansson CEO/Businessman Swedish Strandvagen 43, 4 tr. 114 56 Stockholm Sweden - -------------------------------------------------------------------------------- *Hans Kristian Werdelin Member Board of Directors Danish Novo A/S - -------------------------------------------------------------------------------- Henrik Gurtler Co-CEO Danish Novo A/S - -------------------------------------------------------------------------------- Kurt Anker Nielsen Co-CEO Danish Novo A/S - -------------------------------------------------------------------------------- DIRECTORS AND EXECUTIVE OFFICERS OF FOUNDATION The name, address, title, present principal occupation or employment of each of the directors and executive officers of the Foundation, are set forth below. If no address is given, the director's or officer's address is Brogardsvej 70, Post Box 71, DK-2820 Gentofte, Denmark. The directors are designated with asterisks (*). Name and Citizenship Principal Occupation and Address - -------------------------------------------------------------------------------- *Palle Marcus Chairman of the Board of Directors Danish Novo Nordisk Foundation - -------------------------------------------------------------------------------- *J0rgen Boe Lawyer Danish Margrethevej 6 2960 Rungsted Kyst Denmark - -------------------------------------------------------------------------------- *Mads 0vlisen Member Board of Directors Danish Novo Nordisk Foundation Novo Nordisk A/S Novo Alle, 6B2.22 2880 Bagsvaerd Denmark - -------------------------------------------------------------------------------- Page 9 of 10 Name and Citizenship Principal Occupation and Address - -------------------------------------------------------------------------------- *Niels Borregaard Doctor Danish Enevangen 83 3450 Aller0d Denmark - -------------------------------------------------------------------------------- *Jan Eric Lindsten Doctor Swedish Norr Malarstrand 78, 3 tr. S-112 35 Stockholm Sweden - -------------------------------------------------------------------------------- *Hans Ejvind Hansen Director Danish Hegelsveg 12 2920 Charlottenlund Denmark - -------------------------------------------------------------------------------- *Ulla Morin Technician Danish Novo Nordisk Foundation - -------------------------------------------------------------------------------- *Soren Thuesen Pedersen Chemist Danish Novo Nordisk Foundation - -------------------------------------------------------------------------------- *Stig Strobaek Electrician Danish Novo Nordisk Foundation - -------------------------------------------------------------------------------- Gert Almind Frederiksen CEO Danish Novo Nordisk Foundation - -------------------------------------------------------------------------------- Page 10 of 10 -----END PRIVACY-ENHANCED MESSAGE-----